Floatz logo

Cyclophosphamide

ROS1 Gene Mutation

University of Southern CaliforniaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the ROS1 Gene Mutation cohort.

Asset / SponsorPhaseRating
Epirubicin
University of Southern California
Phase 2B
Carboplatin
Centre Francois Baclesse
Phase 2B
Pembrolizumab
University of Southern California
Phase 2B
Atezolizumab
Centre Francois Baclesse
Phase 2B
VOLITINIB
Hunan Province Tumor Hospital
Phase 2CCC

View all 14 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →